Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

10.52
+0.22002.14%
Pre-market: 10.51-0.0100-0.10%08:55 EDT
Volume:2.09M
Turnover:21.87M
Market Cap:897.50M
PE:-6.03
High:10.63
Open:10.29
Low:10.14
Close:10.30
52wk High:25.77
52wk Low:8.94
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.31
T/O Rate:3.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:1.84
PE(LYR):-22.62

Loading ...

OverviewCompanyNewsFilings

Monte Rosa Therapeutics (GLUE) Receives a Buy from UBS

TIPRANKS
·
Yesterday

Monte Rosa Therapeutics (GLUE) Following Phase 1 Data Faces A Big Fair Value Question

Simply Wall St.
·
Oct 05

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Simply Wall St.
·
Oct 03

Monte Rosa Grants Inducement Equity Awards to New Hires, Including Options for 86,725 Shares at $11.26

Reuters
·
Oct 03

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)

TIPRANKS
·
Oct 02

Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Oct 02

Guggenheim Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Oct 02

Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Oct 02

Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment

Dow Jones
·
Oct 01

Monte Rosa Therapeutics, - to Initiate Multiple Phase 2 Studies of Mrt-8102 in High Unmet Need Indications

THOMSON REUTERS
·
Oct 01

Monte Rosa Therapeutics Announces Positive Results for Mrt-8102 in Gforce-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of Ascvd in Subjects with Elevated CVD Risk

THOMSON REUTERS
·
Oct 01

Monte Rosa Shares Gain Ahead of Clinical Trial Review

Dow Jones
·
Oct 01

Monte Rosa Therapeutics Shares up 18% Premarket After H.c. Wainwright Initiates Coverage with Buy Rating

THOMSON REUTERS
·
Oct 01

Monte Rosa Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $25

THOMSON REUTERS
·
Oct 01

Monte Rosa to Present Phase 1 Gforce-1 Data for MRT-8102 in Elevated Cardiovascular Risk Subjects

Reuters
·
Oct 01

Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush

Dow Jones
·
Sep 09

Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE

TIPRANKS
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

Monte Rosa Therapeutics to receive $50M milestone payment from Novartis

TIPRANKS
·
Sep 08

Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone

Reuters
·
Sep 08
More